<DOC>
	<DOCNO>NCT01445795</DOCNO>
	<brief_summary>This study determine safety Pharmacokinetics ( PK ) Pharmacodynamics ( PD ) INH-08189 dose day ( QD ) , two time day ( BID ) adjunctively Ribavirin study food effect Chronically-infected Genotype 1 Hepatitis C Virus ( HCV ) , Treatment-naïve subject .</brief_summary>
	<brief_title>Safety Study INX-08189 , Pharmacokinetic Pharmacodynamic With Ribavirin Food Effect Study , Chronically-infected Genotype 1 Hepatitis C Virus , Treatment-naïve Subjects</brief_title>
	<detailed_description>Primary Objectives : To evaluate chronically-infected , non-cirrhotic , genotype 1 treatment naïve-subjects dose Study Drug 7 consecutive day Safety - The safety 4 dose cohort INX-08189 ( 200 mg daily ( QD ) , 100 mg twice day ( BID ) , 100 mg QD low-fat meal , 100 mg QD adjunctive ribavirin ) . Pharmacokinetic - To characterize pharmacokinetic ( PK ) profile oral dos INX-08189 ( 200 mg QD , 100 mg BID , 100 mg QD low-fat meal , 100 mg QD adjunctive ribavirin ) PK profile metabolite ( INX-08032 ) . Pharmacodynamic - To evaluate relationship kinetics reduction baseline serum HCV RNA PK parameter INX-08189 metabolite INX-08032 Efficacy - To measure kinetics viral load reduction plasma HCV RNA 4 dose cohort INX-08189 ( 200 mg QD , 100 mg BID , 100 mg QD low-fat meal , 100 mg QD adjunctive ribavirin ) .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>Screening visit ( Visit 1 ) , subject criterion : Males female , 18 65 year age inclusive body mass index ( BMI ) least 18 kg/m2 exceed 36 kg/m2 ; Diagnosed chronic HCV least 1 previous polymerase chain reaction ( PCR ) result prior Visit 1 ( screen ) , positive HCV viral load least 100,000 IU/ml Visit 1 ( screen ) measure quantitative PCR ; HCV genotype 1 per laboratory test report ; HCV treatmentnaïve `` treatmentnaïve '' define prior treatment interferon alpha , pegylated interferon alpha , ribavirin , HCV direct act antiviral drug ; Liver biopsy consistent chronic HCV infection classification noncirrhotic judge pathologist ( define Knodell ≤ 3 , Metavir ≤ 2 , Ishak ≤ 4 , Batts &amp; Ludwig ≤ 2 ) within last 2 year Visit 2 ( biopsy do within screen period ) ; Negative urine drug screen drug abuse ( see Appendix B ; note : methadone allow ) ; Females negative serum beta human chorionic gonadotropin ( βHCG ) pregnancy test screen negative urine dipstick pregnancy test upon entry clinical unit Study Day 1 ; Agreement female subject childbearing potential male subject ( surgically sterilize ) practice acceptable method birth control , include least 1 barrier study least 6 month cessation treatment . Surgical sterilization either female male must occur least 6 month prior first dose female must postmenopausal 2 year consider nonchildbearing potential . Willing able complete study visit procedure , able effectively communicate Investigator test center personnel ; Signed informed consent form ( ICF ) execute prior protocol screen assessment screen visit ( Visit1 ) , subject criterion : Advanced liver disease , cirrhosis , sign decompensated liver disease variceal bleeding , ascites , hepatic encephalopathy , active jaundice define total bilirubin &gt; 2 , evidence decompensated liver disease ; Coinfection hepatitis B virus ( HBV ) human immunodeficiency virus ( HIV ) ( positive test hepatitis B surface antigen [ HBsAg ] antiHIV antibody [ Ab ] ) ; Acute cardiac ischemia , unstable heart disease clinically symptomatic cardiac abnormality apparent electrocardiogram ( ECG ) physical exam , QTcF interval Visit 1 ≥ 450 m Fridericia 's correction , personal family history Torsades de pointes ; Use follow medication concurrently within 30 day prior Screening ( Visit 1 ) associate QT prolongation : macrolides , antiarrhythmic agent , azoles , fluoroquinolones , tricyclic antidepressant ( note : methadone use allow ) ; Use immunosuppressive immunemodulating agent ( include corticosteroid immunosuppressive agent ) presence immunologicallymediated autoimmune disease ( asthma ) history solid organ bone marrow transplantation ( note : inhaled steroid asthma topical steroid minor skin condition allow washout period PO/IM/IV corticosteroid use 8 week ; washout period immunosuppressive determine Medical Monitor ) ; Use strong Cytochrome P ( CYP ) 3A4inhibiting protease inhibitor ( specifically atazanavir , indinavir , nelfinavir , saquinavir , ritonavir ) , strong CYP3A4 inhibitor ( specifically clarithromycin , itraconazole , ketoconazole , nefazodone , telithromycin ) , strong CYP3A4 inducer ( specifically rifampin , efavirenz , etravirine , phenobarbital , phenytoin , carbamazepine ) ; Absolute neutrophil count &lt; 1,800 cells/mm3 , platelet count &lt; 130,000 cells/mm3 , hemoglobin &lt; 12 g/dl woman &lt; 13 g/dl men , history anemia , sickle cell anemia , thalassemia ; ( note : baseline value within 5 % minimum qualifying value , 1 retest allow purpose qualify study ) ; A history abnormal thyroid function adequately control ( define thyroid stimulate hormone [ TSH ] level &lt; 0.8 x low limit normal [ LLN ] &gt; 1.2 x upper limit normal [ ULN ] ) ; Serum creatinine concentration ≥ 1.5 time upper limit normal , albumin ≤ 3 g/dl ; Any history suicide attempt , receipt professional counseling suicidal ideation current suicidal ideation , serious psychiatric disorder ( ie , bipolar disorder , severe depression , psychosis ) requiring require hospitalization medication Any malignancy within last 5 year treat cervical carcinoma situ treat basal cell carcinoma 20 % risk recurrence within 2 year ; Alcohol abuse within past 2 year alcohol use pattern interfere study conduct ; Drug abuse within last 6 month . Current lactation breastfeeding ; Major surgery within 30 day prior Visit 1 ; Participation another clinical trial investigational drug device within 6 month prior visit 1 unless prior participation involve exposure placebo clear available documentation ; Donation blood plasma within 30 day prior Visit 1 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Inhibitex</keyword>
	<keyword>Chronic Hepatitis</keyword>
	<keyword>Hepatitis C Virus</keyword>
</DOC>